Angiokeratomas in Fabry disease.

Hisao Mutoh, MD, PhD, Tadashi Konoshita, MD, PhD,* Tamehito Onoe, MD, PhD, Yasukazu Makino, MD, Kenichiro Arakawa, MD, PhD, and Hiroyuki Nakamura, MD, PhD on behalf of the Genomic Disease Outcome Consortium (G-DOC) Study Investigators *Third Department of Internal Medicine, University of Fukui Faculty of Medical Sciences, Fukui, Japan (E-mail: konosita@u-fukui.ac.jp) The authors have no financial or other conflicts of interest to disclose.

[1]  D. Maixnerova,et al.  A nationwide blood spot screening study for Fabry disease in the Czech Republic haemodialysis patient population. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  I. Miyamori,et al.  A missense mutation, A156T, in the alpha-galactosidase A gene causes typical Fabry disease. , 2001, Clinical nephrology.